Insulin sensitivity, islet cell function, and incretin axis in pregnant women with and without gestational diabetes mellitus

Insulin sensitivity, islet cell function, and incretin axis in pregnant women with and without gestational diabetes mellitus

Introduction: The aim of this study was to compare insulin sensitivity, islet cell function, and incretin axes in pregnant subjects with GDM and normal healthy controls. Methods: Pregnant women at 24 to 28 weeks of gestation were subjected to a 75 g oral glucose tolerance test (OGTT). Samples for gl...

Full description

Bibliographic Details
Main Authors:	Niya Narayanan, Jayaprakash Sahoo, Sadishkumar Kamalanathan, Haritha Sagili, Bobby Zachariah, Dukhabandhu Naik, Ayan Roy, Chandhana Merugu
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2024-01-01
Series:	Indian Journal of Endocrinology and Metabolism
Subjects:	alpha cell beta cell diabetes in pregnancy glucagon glucose-dependent insulinotropic polypeptide glucagon-like peptide-1 insulin secretion and sensitivity index-2
Online Access:	http://www.ijem.in/article.asp?issn=2230-8210;year=2024;volume=28;issue=1;spage=71;epage=79;aulast=Narayanan

Similar Items

Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus
by: Sung Hoon Yu, et al.
Published: (2011-02-01)

The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects
by: Akihiro Hamasaki, et al.
Published: (2024-06-01)

Assessing the Effect of Incretin Hormones and Other Insulin Secretagogues on Pancreatic Beta-Cell Function: Review on Mathematical Modelling Approaches
by: Giovanni Pacini, et al.
Published: (2022-05-01)

Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes
by: Chang Ho Ahn, et al.
Published: (2023-02-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01)

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
by: Katherine O. Kopp, et al.
Published: (2024-07-01)

Tirzepatide – a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023-10-01)

Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01)

Insulin and incretin responses to grazing in insulin‐dysregulated and healthy ponies
by: Danielle M. Fitzgerald, et al.
Published: (2019-01-01)

Incretin secretion and glucose metabolism in morbidly obese patients in the early and late periods after biliopancreatic diversion
by: I I Dedov, et al.
Published: (2016-10-01)

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
by: Jang Won Son, et al.
Published: (2024-04-01)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion in humans: Characteristics and regulation
by: Wathik Alsalim, et al.
Published: (2023-03-01)

Roles of glucose‐dependent insulinotropic polypeptide in diet‐induced obesity
by: Yusuke Seino, et al.
Published: (2022-07-01)

Updates of incretin‐related drugs for the treatment of type 2 diabetes
by: Hirotaka Araki, et al.
Published: (2023-02-01)

Genetic variability of incretin receptors affects the occurrence of neurodegenerative diseases and their characteristics
by: David Vogrinc, et al.
Published: (2024-10-01)

Incretins today: multiple effects and therapeutic potential
by: Oksana V. Tsygankova, et al.
Published: (2019-03-01)

Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses
by: Line Engelbrechtsen, et al.
Published: (2018-03-01)

Non-altered incretin secretion in women with impaired fasting plasma glucose in the early stage of pregnancy: a case control study
by: Ondrej Krystynik, et al.
Published: (2023-01-01)

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
by: Tsuyoshi Yanagimachi, et al.
Published: (2020-04-01)

Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury
by: Miaad Bader, et al.
Published: (2020-01-01)

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
by: Martin Haljeta Friedrichsen, et al.
Published: (2023-12-01)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024-06-01)

Does Incretin Agonism Have Sustainable Efficacy?
by: Sok-Ja Janket, et al.
Published: (2024-11-01)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
by: Szymon Jonik, et al.
Published: (2022-02-01)

Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis
by: Akira Mima, et al.
Published: (2023-03-01)

Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
by: Jared Rosenberg, et al.
Published: (2021-09-01)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
by: Rizvi AA, et al.
Published: (2022-04-01)

Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
by: Alessia Costa, et al.
Published: (2022-01-01)

DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes
by: Kozlovski P, et al.
Published: (2017-03-01)

Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”
by: Tian-Yi Ren, et al.
Published: (2024-10-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
by: Alexandros Leonidas Liarakos, et al.
Published: (2023-07-01)

Serum Levels of Incretin Hormones – GLP-1 and GIP in Patients with Type 1 Diabetes Mellitus
by: Stanchev Pavel E., et al.
Published: (2019-03-01)

Variation in responses to incretin therapy: Modifiable and non-modifiable factors
by: Gregory O. Austin, et al.
Published: (2023-04-01)

Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block
by: Jun Sung Moon, et al.
Published: (2015-02-01)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
by: Vijaya Subramanian, et al.
Published: (2022-09-01)

Stimulatory effect of imeglimin on incretin secretion
by: Quan Yingyue, et al.
Published: (2023-06-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-12-01)